The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer
The direct effect of TSH on bone metabolism in vivo is difficult to capture as the changes of its concentrations are followed by respective alterations of thyroid hormone levels. We evaluated the effect of recombinant human TSH (rhTSH) on sclerostin and other bone markers in 29 patients after total...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-10-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/21/4905 |
_version_ | 1797512284309815296 |
---|---|
author | Arkadiusz Zygmunt Kinga Krawczyk-Rusiecka Elżbieta Skowrońska-Jóźwiak Katarzyna Wojciechowska-Durczyńska Ewa Głowacka Zbigniew Adamczewski Andrzej Lewiński |
author_facet | Arkadiusz Zygmunt Kinga Krawczyk-Rusiecka Elżbieta Skowrońska-Jóźwiak Katarzyna Wojciechowska-Durczyńska Ewa Głowacka Zbigniew Adamczewski Andrzej Lewiński |
author_sort | Arkadiusz Zygmunt |
collection | DOAJ |
description | The direct effect of TSH on bone metabolism in vivo is difficult to capture as the changes of its concentrations are followed by respective alterations of thyroid hormone levels. We evaluated the effect of recombinant human TSH (rhTSH) on sclerostin and other bone markers in 29 patients after total thyroidectomy for differentiated thyroid cancer (DTC), without any signs of disease recurrence, who received L-thyroxine, most at non-suppressive doses. For two consecutive days, the patients were administered a standard dose of 0.9 mg rhTSH, i.m. Concentrations of sclerostin, osteocalcin, β-CrossLaps, PTH, and some other parameters, were measured before and five days after the first rhTSH administration. The greater the increase in TSH concentration (∆TSH), the greater the decrease in: ∆sclerostin (r = −0.672; <i>p</i> < 0.001), ∆β-CrossLaps (r = −0.580; <i>p</i> < 0.001) and ∆osteocalcin (r = −0.405; <i>p</i> = 0.029) levels, were recorded. The degree of TSH increase depended on the baseline PTH (r = 0.651; <i>p</i> < 0.001), age, and creatinine concentrations. rhTSH strongly inhibited bone turnover, thus, TSH—independently of thyroid hormones—exerted a direct protective effect on bone metabolism. Baseline PTH affected the magnitude of TSH increase and the degree of lowering in sclerostin and β-CrossLaps that suggest factors affecting PTH may play a role in the effect of TSH on the bone. |
first_indexed | 2024-03-10T05:59:43Z |
format | Article |
id | doaj.art-5d4f77d22540431abe6dbcb240cd082c |
institution | Directory Open Access Journal |
issn | 2077-0383 |
language | English |
last_indexed | 2024-03-10T05:59:43Z |
publishDate | 2021-10-01 |
publisher | MDPI AG |
record_format | Article |
series | Journal of Clinical Medicine |
spelling | doaj.art-5d4f77d22540431abe6dbcb240cd082c2023-11-22T21:04:24ZengMDPI AGJournal of Clinical Medicine2077-03832021-10-011021490510.3390/jcm10214905The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid CancerArkadiusz Zygmunt0Kinga Krawczyk-Rusiecka1Elżbieta Skowrońska-Jóźwiak2Katarzyna Wojciechowska-Durczyńska3Ewa Głowacka4Zbigniew Adamczewski5Andrzej Lewiński6Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, 93-338 Lodz, PolandDepartment of Endocrinology and Metabolic Diseases, Medical University of Lodz, 93-338 Lodz, PolandDepartment of Endocrinology and Metabolic Diseases, Medical University of Lodz, 93-338 Lodz, PolandDepartment of Endocrinology and Metabolic Diseases, Medical University of Lodz, 93-338 Lodz, PolandDepartment of Laboratory Diagnostics, Research Institute, Polish Mother’s Memorial Hospital, 93-338 Lodz, PolandDepartment of Endocrinology and Metabolic Diseases, Research Institute, Polish Mother’s Memorial Hospital, 93-338 Lodz, PolandDepartment of Endocrinology and Metabolic Diseases, Medical University of Lodz, 93-338 Lodz, PolandThe direct effect of TSH on bone metabolism in vivo is difficult to capture as the changes of its concentrations are followed by respective alterations of thyroid hormone levels. We evaluated the effect of recombinant human TSH (rhTSH) on sclerostin and other bone markers in 29 patients after total thyroidectomy for differentiated thyroid cancer (DTC), without any signs of disease recurrence, who received L-thyroxine, most at non-suppressive doses. For two consecutive days, the patients were administered a standard dose of 0.9 mg rhTSH, i.m. Concentrations of sclerostin, osteocalcin, β-CrossLaps, PTH, and some other parameters, were measured before and five days after the first rhTSH administration. The greater the increase in TSH concentration (∆TSH), the greater the decrease in: ∆sclerostin (r = −0.672; <i>p</i> < 0.001), ∆β-CrossLaps (r = −0.580; <i>p</i> < 0.001) and ∆osteocalcin (r = −0.405; <i>p</i> = 0.029) levels, were recorded. The degree of TSH increase depended on the baseline PTH (r = 0.651; <i>p</i> < 0.001), age, and creatinine concentrations. rhTSH strongly inhibited bone turnover, thus, TSH—independently of thyroid hormones—exerted a direct protective effect on bone metabolism. Baseline PTH affected the magnitude of TSH increase and the degree of lowering in sclerostin and β-CrossLaps that suggest factors affecting PTH may play a role in the effect of TSH on the bone.https://www.mdpi.com/2077-0383/10/21/4905thyrotropinsclerostinparathormonbone turnover markers |
spellingShingle | Arkadiusz Zygmunt Kinga Krawczyk-Rusiecka Elżbieta Skowrońska-Jóźwiak Katarzyna Wojciechowska-Durczyńska Ewa Głowacka Zbigniew Adamczewski Andrzej Lewiński The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer Journal of Clinical Medicine thyrotropin sclerostin parathormon bone turnover markers |
title | The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer |
title_full | The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer |
title_fullStr | The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer |
title_full_unstemmed | The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer |
title_short | The Effect of Recombinant Human TSH on Sclerostin and Other Selected Bone Markers in Patients after Total Thyroidectomy for Differentiated Thyroid Cancer |
title_sort | effect of recombinant human tsh on sclerostin and other selected bone markers in patients after total thyroidectomy for differentiated thyroid cancer |
topic | thyrotropin sclerostin parathormon bone turnover markers |
url | https://www.mdpi.com/2077-0383/10/21/4905 |
work_keys_str_mv | AT arkadiuszzygmunt theeffectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer AT kingakrawczykrusiecka theeffectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer AT elzbietaskowronskajozwiak theeffectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer AT katarzynawojciechowskadurczynska theeffectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer AT ewagłowacka theeffectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer AT zbigniewadamczewski theeffectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer AT andrzejlewinski theeffectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer AT arkadiuszzygmunt effectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer AT kingakrawczykrusiecka effectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer AT elzbietaskowronskajozwiak effectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer AT katarzynawojciechowskadurczynska effectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer AT ewagłowacka effectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer AT zbigniewadamczewski effectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer AT andrzejlewinski effectofrecombinanthumantshonsclerostinandotherselectedbonemarkersinpatientsaftertotalthyroidectomyfordifferentiatedthyroidcancer |